Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry's biggest blockbusters. On Wednesday, the Boston-area biotech said that its experimental drug ...

A global survey of breast cancer patients reveals a gap in support services for managing the mental and physical side effects experienced by those undergoing treatment.

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

Providing coverage for weight-loss drugs such as Wegovy and Ozempic is forcing employers to make some critical decisions.

Losing weight can bolster confidence, but it can also impact how others treat you. Knowing how to manage relationships and ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

Hoping your company will begin paying for anti-obesity medications like Wegovy? You may be in luck. A growing number of ...

GLP-1 agonists work by triggering the pancreas to produce more insulin, which reduces blood sugar levels in those with type 2 ...

Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.

India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...